[Ad hoc announcement pursuant to Art. 53 LR] Roche’s Tecentriq plus Avastin is the first treatment combination to reduce the risk of cancer returning in people with certain types of early-stage liver cancer in a Phase III trial January 19, 2023January 19, 2023 by / Share This.....LinkedinTwitterFacebookGoogleEmailRelated News: Ad hoc announcement pursuant to Art. 53 LR Roche…[Ad hoc announcement pursuant to Art. 53 LR] Phase…Pivotal Phase III data at ASCO show Roche’s…[Ad hoc announcement pursuant to Art. 53 LR] Roche…[Ad hoc announcement pursuant to Art. 53 LR] Roche…Eight-year data from APHINITY study show Roche’s…Share this:Click to share on Twitter (Opens in new window)Click to share on Facebook (Opens in new window)
